CXCR3 and autoimmune hepatitis: In a study on AIH-2 mice, it was found that targeting FTCD with ex vivo expanded CXCR3+ Tregs was successful in restoring peripheral tolerance to FTCD autoantigens and causing remission in AIH mice [127].